With the continuous development and growth of the biopharmaceutical industry, procurement management has become an indispensable part of enterprise management. In order to improve procurement efficiency, reduce procurement costs, and ensure procurement quality and compliance, enterprises need to change the traditional procurement mode and upgrade the procurement management through Digital transformation. Biopharmaceutical companies face the following difficulties in procurement management: The procurement process is complex: biopharmaceutical procurement involves multiple stages, including requirement confirmation, supplier selection, contract signing, order processing, receipt and acceptance, etc. The process is complex and prone to problems such as information asymmetry and poor communication. Difficulty in

In recent years, we have heard such new terms as “national centralized procurement”, “4+7”, and “centralized procurement of drugs” in hospitals or pharmacies. What is national centralized procurement? What benefits does national centralized procurement bring to our people? The reporter conducted a special interview with Ye Jinlin, a pharmacist at Guangdong Second Middle School Hospital, who provided readers with detailed explanations. National centralized procurement policy, making medication more affordable for the general public On April 1, 2019 and April 27, 2020, the first and second batches of national centralized procurement drugs were officially launched in Guangdong. Perhaps these days should

Pharmaceutical companies related to COVID-19 rose sharply today. Jiangsu Hengrui Medicine announced that it plans to buy back shares of 600 million yuan to 1.2 billion yuan. In addition, there are also news to stimulate the market. For example, Everbright Securities released a research report that the American Society of Clinical Oncology (ASCO) conference will be held in Chicago, the United States, from June 2 to 6. Invited by the conference, multiple star pharmaceutical companies in China will soon disclose the latest clinical data of multiple products at the ASCO conference (2023), covering a wide range of disease fields, such

On May 16th, the Kangmei China Traditional Chinese Medicine Price Index was at 1987.3 points, while the previous day, the index was at 1988.14 points, setting its highest historical value since its release in 2013. Previously, CCTV Finance reported that the Chinese herbal medicine market experienced a bull market in the first quarter, with downstream pharmaceutical companies experiencing a sharp increase in procurement costs, and some Chinese herbal medicines experiencing “three prices per day”. According to multiple Chinese medicine pharmaceutical listed companies, respondents all stated that the price increase of Chinese medicine is mainly due to weather factors, coupled with